recurrent findings in advanced human ovarian cancer. Genes Chromosomes
Cancer 16: 46–54.
42. Sonoda G, Palazzo J, du Manoir S, Godwin AK, Feder M, et al. (1997)
Comparative genomic hybridization detects frequent overrepresentation of
chromosomal material from 3q26, 8q24, and 20q13 in human ovarian
carcinomas. Genes Chromosomes Cancer 20: 320–328.
43. Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, et al. (2003) Specific
keynote: genome copy number abnormalities in ovarian cancer. Gynecol
Oncol 88: S16–21; discussion S22–14.
44. Caserta D, Benkhalifa M, Baldi M, Fiorentino F, Qumsiyeh M, et al. (2008)
Genome profiling of ovarian adenocarcinomas using pangenomic BACs
microarray comparative genomic hybridization. Mol Cytogene t 1: 10.
45. Kim SW, Kim JW, Kim YT, Kim JH, Kim S, et al. (2007) Analysis of
chromosomal changes in serous ovarian carcinoma using high-resolution array
comparative genomic hybridization: Potential predictive markers of chemore-
sistant disease. Genes Chromosomes Cancer 46: 1–9.
46. Nowee ME, Snijders AM, Rockx DA, de Wit RM, Kosma VM, et al. (2007)
DNA profiling of primary serous ovarian and fallopian tube carcinomas with
array comparative genomic hybridization and multiplex ligation-dependent
probe amplification. J Pathol 213: 46–55.
47. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, et al. (2007) High-
resolution single nucleotide polymorphism array analysis of epithelial ovarian
cancer reveals numerous microdeletions and amplifications. Clin Cancer Res
48. Sotiriou C, Piccart MJ (2007) Taking gene-expression profiling to the clinic:
when will molecular signatures become relevant to patient care? Nat Rev
Cancer 7: 545–553.
49. Straehle C, Cardoso F, Azambuja E, Dolci S, Meirsman L, et al. (2009) Better
translation from bench to bedside: breakthroughs in the individualized
treatment of cancer. Crit Care Med 37: S22–29.
50. Gabeau-Lacet D, Engler D, Gupta S, Scangas GA, Betensky RA, et al. (2009)
Genomic profiling of atypical meningiomas associates gain of 1q with poor
clinical outcome. J Neuropathol Exp Neurol 68: 1155–1165.
51. Zhang L, Huang J, Yang N, Liang S, Barchetti A, et al. (2006) Integrative
genomic analysis of protein kinase C (PKC) family identifies PKCiota as a
biomarker and potential oncogene in ovarian carcinoma. Cancer Res 66:
52. Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary
segmentation for the analysis of array-based DNA copy number data.
Biostatistics 5: 557–572.
53. Korkola JE, Heck S, Olshen AB, Reuter VE, Bosl GJ, et al. (2008) In vivo
differentiation and genomic evolution in adult male germ cell tumors. Genes
Chromosomes Cancer 47: 43–55.
54. van de Wiel MA, van Wieringen WN (2007) CGHregions: dimension reduction
for array CGH data with minimal informatics loss. Cancer Informatics 2:
55. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007)
Assessing the significance of chromosomal aberrations in cancer: methodology
and application to glioma. Proc Natl Acad Sci U S A 104: 20007–20012.
56. Dimitriadou E, Hornik K, Leisch F, Meyer D, Weingessel A (2006) e1071:
Misc Functions of the Department of Statistics (e1071), TU Wien.
57. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth W A, et al. (2008) Dicer,
Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359:
58. Farley J, Fuchiuji S, Darcy KM, Tian C, Hoskins WJ, et al. (2009) Associations
between ERBB2 amplificatio n and progression-free survival and overall
survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a
Gynecologic Oncology Group Study. Gynecol Oncol 113: 341–347.
59. Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment
of ovarian carcin oma. Natl Cancer Inst Monogr 42: 101–104.
60. Krag KJ, Canel los GP, Griffiths CT, Knapp RC, Parker LM, et al. (1989)
Predictive factors for long-term survival in patients with advanced ovarian
cancer. Gynecol Oncol 34: 88–93.
61. Ramaswamy S, Golub TR (2002) DNA microarrays in clinical oncology. J Clin
Oncol 20: 1932–1941.
62. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated
observation of breast tumor subtypes in independent gene expression data sets.
Proc Natl Acad Sci U S A 100: 8418–8423.
63. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, et al. (2006)
Genomic and transcriptional aberrations linked to breast cancer pathophys-
iologies. Cancer Cell 10: 529–541.
64. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, et al. (2004) Gene
expression signature with independent prognostic significance in epithelial
ovarian cancer. J Clin Oncol 22: 4700–4710.
65. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, et al. (2008)
A gene signature predicting for survival in suboptimally debulked patients with
ovarian cancer. Cancer Res 68: 5478–5486.
66. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, et al. (2009) Microarray
analysis of early stage serous ovarian cancers shows profiles predictive of
favorable outcome. Clin Cancer Res 15: 2448–2455.
67. Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, et al. (2009)
Gene expression profiling of advanced-stage serous ovarian cancers distin-
guishes novel subclasses and implicates ZEB2 in tumor progression and
prognosis. Cancer Sci 100: 1421–1428.
68. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, et al. (2011) Integrated
genomic analyses of ovarian carcinoma. Nature 474: 609–615.
69. C uenda A (2000) Mitogen-activated protein kinase kinase 4 (MKK4).
Int J Biochem Cell Biol 32: 581–587.
70. Yamada SD, Hickson JA, Hrobowski Y, Vander Griend DJ, Benson D, et al.
(2002) Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis
suppressor gene in human ovarian carcinoma. Cancer Res 62: 6717–6723.
71. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, et al. (2005)
Colorectal cancer: mutations in a signalling pathway. Nature 436: 792.
72. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007)
Patterns of somatic mutation in human cancer genomes. Nature 446: 153–158.
73. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. (2010) Diverse
somatic mutation patterns and pathway alterations in human cancers. Nature
74. Cazillis M, Bringuier AF, Delautier D, Buisine M, Bernuau D, et al. (2004)
Disruption of MKK4 signaling reveals its tumor-suppressor role in embryonic
stem cells. Oncogene 23: 4735–4744.
75. Lefebvre V, Li P, de Crombrugghe B (1998) A new long form of Sox5 (L-Sox5),
Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate
the type II collagen gene. Embo J 17: 5718–5733.
76. Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, et al. (2008) Transcription
factor SOX-5 enhances nasopharyngeal carcinoma progression by down-
regulating SPARC gene expression. J Pathol 214: 445–455.
77. Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, et al. (1996)
ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell
cycle regulation in yeast. Proc Natl Acad Sci U S A 93: 7143–7148.
78. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, et al. (2009) Identification of genes
with differential expression in chemoresistant epithelial ovarian cancer using
high-density oligonucleotide microarrays. Oncol Res 18: 47–56.
79. Zhou W, Feng X, Li H, Wang L, Li H, et al. (2007) Functional evidence for a
nasopharyngeal carcinoma-related gene BCAT1 located at 12p12. Oncol Res
80. Yoshikawa R, Yanagi H, Shen CS, Fujiwara Y, Noda M, et al. (2006) ECA39 is
a novel distant metastasis-related biomarker in colorectal cancer.
World J Gastroenterol 12: 5884–5889.
81. Liu P, Wang Y, Vikis H, Maciag A, Wang D, et al. (2006) Candidate lung
tumor susceptibility genes identified throu gh whole-genome association
analyses in inbred mice. Nat Genet 38: 888–895.
82. Bos JL (1988) The ras gene family and human carcinogenesis. Mutat Res 195:
83. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001)
Somatic activation of the K-ras oncogene causes early onset lung cancer in
mice. Nature 410: 1111–1116.
84. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, et al. (2005) Role
of K-ras and Pten in the development of mouse models of endometriosis and
endometrioid ovarian cancer. Nat Med 11: 63–70.
85. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, et al. (2007) Dose-
dependent oncogene-induced senescence in vivo and its evasion during
mammary tumorigenesis. Nat Cell Biol 9: 493–505.
86. Farley J, Smith LM, Darcy KM, Sobel E, O’Connor D, et al. (2003) Cyclin E
expression is a significant predictor of survival in advanced, suboptimally
debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.
Cancer Res 63: 1235–1241.
87. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995)
Human cyclin E, a nuclear protein essential for the G1-to-S phase transition.
Mol Cell Biol 15: 2612–2624.
88. Resnitzky D, Hengst L, Reed SI (1995) Cyclin A-associated kinase activity is
rate limiting for entrance into S phase and is negatively regulated in G1 by
p27Kip1. Mol Cell Biol 15: 4347–4352.
89. Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, et al. (2004) Induction
of centrosome amplification and chromosome instability in human bladder
cancer cells by p53 mutation and cyclin E overexpression. Cancer Res 64:
90. Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, et al. (2010)
Gene amplific ation CCNE1 is related to poor survival and potential
therapeutic target in ovarian cancer. Cancer 116: 2621–2634.
91. Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, et al. (2000) A role for Id-
1 in the aggressive phenotype and steroid hormone response of human breast
cancer cells. Canc er Res 60: 1332–1340.
92. Schoppmann SF, Schindl M, Bayer G, Aumayr K, Dienes J, et al. (2003)
Overexpression of Id-1 is associated with poor clinical outcome in node
negative breast cancer. Int J Cancer 104: 677–682.
93. Qian Y, Chen X (2008) ID1, inhibitor of differentiation/DNA binding, is an
effector of the p53-dependent DNA damage response pathway. J Biol Chem
94. Schindl M, Schoppmann SF, Strobel T, Heinzl H, Leisser C, et al. (2003) Level
of Id-1 protein expression correlates with poor differentiation, enhanced
malignant potential, and more aggressive clinical behavior of epithelial ovarian
tumors. Clin Canc er Res 9: 779–785.
95. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, et al. (1993)
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic
cell death. Cell 74: 597–608.
DNA Copy Number in Ovarian Carcinoma
PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e30996